CSI Market
Sign In | Register

10x Genomics Inc (TXG) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TXG quarterly Cash Flow →
The data below summarizes 10x Genomics Inc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-43.54
Depreciation & amortization36.20
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.75
Restructuring Costs and Asset Impairment Charges1.25
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories27.95
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation109.12
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Increase Decrease In Accrued Contingent Liabilities-
Finance Lease Right Of Use Asset Amortization7.62
Increase Decrease In Accrued Liabilities And Other Current Liabilities0.81
Increase Decrease In Operating Lease Liability-
Increase Decrease In Operating Lease Liability-
Income taxes-1.75
Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments, Total0.00
Accounts Receivable14.09
Increase (Decrease) in Accounts Payable-2.13
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.34
Other Working Capital2.09
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-14.06
Discontinued operations0.00
Net Cash flow from Operating Activities136.05
Investing Activities
Capital Expenditures-5.94
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities125.20
Payments to Acquire Available-for-sale Securities, Debt-123.44
Real Estate Investments0.00
Payments For Asset Acquisition Net Of Cash Acquired-9.27
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-13.44
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock6.80
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-344.07
Payments On Capital Lease Obligations-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents344.07
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.80
Effect of exchange rate on cash flow0.48
Discontinued operations0.00
Free Cash Flow130.12
Total Cash Flow129.90
4 historic quarters locked

Sign in to unlock the full 10x Genomics Inc cash flow history.

Sign In Create Free Account

About 10x Genomics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 12, 2026
  • Source: txg-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-007822

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License